Current Clinical Trials for Adults with Brain Tumor
UCSF Cancer Center • UCSF Brain Tumor Program
Department of Neurological Surgery & Brain Tumor Research Center

Questions about patients' participation in the following clinical trials can be directed to Jane Rabbitt or Margaretta Page by calling 415-353-2966, or by email to Mary Malec at malecm@neurosurg.ucsf.edu.

For further details about clinical trials for adults being performed through the North American Brain Tumor Consortium (NABTC), visit: <http://www.nabtc.org/>

Newly Diagnosed High-Grade Glioma

Phase II Study of PolyICLC plus Radiation for Newly Diagnosed Patients with Glioblastoma Multiforme (NABTC 01-05)

Phase I Study of R115777 plus Radiation for Newly Diagnosed Patients with Glioblastoma Multiforme (NABTC 02-02)

A Phase I/III Randomized Study of Radiation Therapy and Temozolomide vs Radiation Therapy and BCNU vs Radiation Therapy and Temozolomide and BCNU for Anaplastic Astrocytoma (RTOG 9813)

Phase I Study of Convection-Enhanced Delivery (CED) of IL13-PE38QQR Cytotoxin after Resection and prior to Radiation Therapy with or without Temozolomide in Patients with Newly Diagnosed Supratentorial Malignant Glioma

Newly Diagnosed Low-Grade Glioma

A Phase I Study of Temozolomide (SCH 52365) in the Treatment of Adult Patients with Supratentorial Low-Grade Glioma

Recurrent Tumor

Phase I/II Trial of CCI-779 in Patients with Malignant Glioma (NABTC 01-01)

ZD 1893 for Treatment of Recurrent or Progressive Malignant Astrocytoma or Glioblastoma and Recurrent or Progressive Meningioma: A Phase II Study with a Phase I Component for Patients Receiving EIAEDs (NABTC 00-01)

Recurrent Tumor, continued

A Phase I/II Trial of OSI-774 in Patients with Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy (NABTC 01-03)

A Phase II Trial of Poly ICLC in Patients with Recurrent Anaplastic Glioma (NABTC 01-06)

A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme [that has] Recurred or Progressed After Previous Resection and Radiation Therapy and [is] Scheduled for Gross Total Resection

Phase II, Multicenter, Open-Label Trial of the Safety and Efficacy of Tarceva (Erlotinib Hydrochloride) in Patients with First Relapse of Grade IV Glioma (Glioblastoma Multiforme) (OSI2691G)

Phase II Trial of STI571 in Patients with Recurrent Meningioma (NABTC 01-08)

Phase III Randomized Evaluation of Convection-Enhanced Delivery of IL13-PEQQR Compared to Gliadel Wafer with Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence

A Phase I/II, Two-Arm, Multicenter, Dose-Escalation Study [of] Oral AEE788 Administered on a Continuous Once-Daily Dosing Schedule in Adult Patients with Recurrent or Relapsing Glioblastoma Multiforme

A Phase II Trial of EMD 121974 for Recurrent Glioblastoma: a Clinical Trial with Tissue Correlates of Response (NABTC 03-02)

Non-Chemotherapy Protocols

Assessment of Needs for [a] Complementary Medicine Program for Patients with Brain Tumors

San Francisco Bay Area Adult Glioma Prognosis Study

A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas (NABTC 01-07)
Questions about patients' participation in the following clinical trials can be directed to Jane Rabbitt or Margaretta Page by calling 415-353-2966, or by email to Mary Malec at malecm@neurosurg.ucsf.edu.

For further details about clinical trials for children being performed through the Pediatric Brain Tumor Consortium (PBTC), visit: <http://www.pbtc.org/>

Pilot Study of Systemic and Intrathecal Chemotherapy Followed by Conformal Radiation for Infants with Embryonal Intracranial Central Nervous System Tumors: a Pediatric Brain Tumor Consortium Protocol (PBTC 001)

This is a risk-adapted, multi-modality trial for patients under the age of 3 years newly diagnosed with medulloblastoma/primitive neuroectodermal tumor (PNET), metastatic ependymoma, or other primary intracranial embryonal tumors. For further details: <http://www.pbtc.org/public/PBTC001_patient_abstract.htm>

Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients with Recurrent Brain Tumors (PBTC 005)

This is a phase I trial for patients with recurrent or refractory pediatric brain tumors. For further details: <http://www.pbtc.org/public/PBTC005_HP_abstract.htm>

Phase I/II Trial of ST1571 in Children with Newly Diagnosed Poor Prognosis Brainstem Glioma and Recurrent Intracranial Malignant Glioma (PBTC 006)

This is a phase I/II trial open to patients 3 to 21 years old. For further details: <http://www.pbtc.org/public/PBTC006_HP_abstract.htm>

Phase I/II Trial of ZD1839 (Iressa™) and Radiation in Pediatric Patients Newly Diagnosed with Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas with Phase II Limited to Brain Stem Tumors (PBTC007)

Children with newly diagnosed intrinsic brain stem gliomas and incompletely resected supratentorial malignant gliomas with residual tumor on imaging are eligible for this study. For further details: <http://www.pbtc.org/public/PBTC007_HP_abstract.htm>

Phase I Study of Cilengitide (EMB 121974) in Pediatric Patients with Refractory Brain Tumors (PBTC 012)

This is a phase I dose-escalation study of the anti-angiogenesis agent cilengitide, a potent and selective cyclized RGD pentapeptide antagonist of the integrins avß3 and avß5, in children with brain tumors refractory to standard therapy. For further details: http://www.pbtc.org/public/PBTC012_HP_abstract.htm

For further details about clinical trials for children being performed at UCSF, visit <http://www.cc.ucsf.edu/trials/peds_brain_toc.html>

Brain Tumor Therapy at UCSF is a collaboration of UCSF's Neurological Surgery, Neuro-Oncology, Radiation Oncology, Gamma Knife®, and Pediatric Programs, with the support of researchers in UCSF’s Brain Tumor Research Center (BTRC) and Michael Douglas Pediatric BTRC, and with close ties to organizations sponsoring support groups and other resources for patients with brain tumors.